Barinthus Biotherapeutics (NASDAQ:BRNS) Rating Reiterated by HC Wainwright

Barinthus Biotherapeutics (NASDAQ:BRNS)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 323.69% from the stock’s current price.

A number of other equities research analysts also recently issued reports on the stock. Barclays reduced their price objective on shares of Barinthus Biotherapeutics from $7.00 to $3.00 and set an “overweight” rating on the stock in a research note on Thursday, June 13th. William Blair reiterated an “outperform” rating on shares of Barinthus Biotherapeutics in a research report on Thursday, June 13th. Finally, Alliance Global Partners lowered their price objective on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a research report on Tuesday, August 13th.

Barinthus Biotherapeutics Trading Down 1.7 %

NASDAQ BRNS opened at $1.18 on Thursday. The firm’s fifty day moving average price is $1.32 and its two-hundred day moving average price is $1.87. Barinthus Biotherapeutics has a 1 year low of $1.11 and a 1 year high of $5.10. The firm has a market capitalization of $46.52 million, a P/E ratio of -0.66 and a beta of -0.53.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.01). On average, research analysts anticipate that Barinthus Biotherapeutics will post -1.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Alphabet Inc. acquired a new position in shares of Barinthus Biotherapeutics in the second quarter worth approximately $2,119,000. Catalina Capital Group LLC acquired a new position in shares of Barinthus Biotherapeutics in the 2nd quarter worth approximately $25,000. Ipswich Investment Management Co. Inc. bought a new stake in shares of Barinthus Biotherapeutics in the 2nd quarter valued at $32,000. M&G Plc acquired a new stake in shares of Barinthus Biotherapeutics during the second quarter worth $7,276,000. Finally, BlueCrest Capital Management Ltd bought a new position in Barinthus Biotherapeutics during the first quarter worth $1,292,000. 25.20% of the stock is owned by institutional investors and hedge funds.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.